Anti-Mucin6 protein monoclonal antibody as well as preparation method and application thereof

By developing anti-Mucin6 protein monoclonal antibodies, the specificity and sensitivity of anti-Mucin6 protein detection in the prior art were solved, and more accurate immunohistochemical detection of gastric adenocarcinoma was achieved, and tumor typing and prognosis evaluation were improved. .

CN119060186AActive Publication Date: 2024-12-03FUZHOU MAIXIN BIOTECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411489093.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-24
Publication Date
2024-12-03
Estimated Expiration
2044-10-24

AI Technical Summary

Technical Problem

The existing anti-Mucin6 protein detection technology has insufficient specificity and sensitivity in the pathological diagnosis of gastrointestinal tumors, making it difficult to accurately identify the expression of Mucin6 protein, affecting the tumor typing, staging and prognosis evaluation.

Method used

A monoclonal antibody against Mucin6 protein was developed. By selecting amino acid fragments at the 1950-2050 site of Mucin6 protein, it was recombinantly expressed and expressed in E. coli. The obtained recombinant protein was used to immunize mice and screened for high specificity. monoclonal antibodies of sexual and sensitive nature, used in immunologic testing, especially immunohistochemistry testing.

Benefits of technology

This monoclonal antibody can efficiently recognize Mucin6 protein, improves the specificity and sensitivity of immunohistochemical detection of gastric adenocarcinoma, reduces false negative results, and provides more accurate tumor typing and prognosis evaluation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060186A_ABST
    Figure CN119060186A_ABST
Patent Text Reader

Abstract

The invention relates to a monoclonal antibody capable of recognizing a human Mucin6 antigen, a preparation method of the monoclonal antibody and application of the monoclonal antibody in immunodetection. According to the technical scheme, 1950-2050 amino acids of the Mucin6 protein are selected as antigen peptides, codon optimization is carried out, a gene segment suitable for being expressed in escherichia coli BL21 is formed, and the finally obtained recombinant protein comprises a Mucin6 protein segment and a histidine tag. A mouse is immunized by the recombinant protein, and a mouse hybridoma cell strain 37D10 and an anti-Mucin6 protein monoclonal antibody secreted by the cell strain are obtained through cell fusion, screening and subcloning. The antibody obtained by the scheme has high specificity and sensitivity, can specifically recognize cells expressing Mucin6 protein, and is suitable for immunological detection, especially immunohistochemical detection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical engineering, and in particular to an anti-Mucin6 protein monoclonal antibody and a preparation method and application thereof. Background Art

[0002] Mucin 6 (MUC6) is a secretory mucin. Its encoding gene is located in the short arm of chromosome 11, region 1, band 5, and encodes a protein containing 2439 amino acid residues, including a cysteine-rich N-terminal domain, a highly glycosylated domain rich in serine, threonine, and proline, and a C-terminal cystine knot, which plays an important role in the formation of MUC6 oligomers. Under physiological conditions, mucin MUC6 is mainly expressed in normal gastric mucosal tissue, playing a role in lubricating and protecting the gastric mucosa. However, with the deepening of research, it was found that MUC6 is abnormally expressed in a variety of tumors and plays an important role in the occurrence and development of tumors. In addition to the protein skeleton of all mucins, namely the mucin core peptide and a large number of sugar chains connected to the core peptide, MUC6 also usually has O-glycans containing α1,4-linked N-acetylglucosamine residues (αGlcNAc) attached to its structure. This special structure plays an important role in the function of MUC6. As the importance of MUC6 in the pathological process of tumors becomes more prominent, its role in the biological behavior of tumors has also been further explained. All of these have laid the foundation for a deeper understanding of the role and mechanism of MUC6, and at the same time provided a research foundation and theoretical basis for the prevention, early diagnosis and treatment monitoring of tumors.

[0003] Studies have shown that in gastrointestinal tumors, the expression of MUC6 varies depending on the tumor type and stage. During the occurrence and development of gastric cancer, the expression of MUC6 protein is gradually lost. The expression of MUC6 may be related to the Lauren classification, degree of differentiation, degree of tumor invasion and stage of the tumor. Studies have shown that the expression of MUC6 in mixed gastric cancer is higher than that in intestinal and diffuse gastric cancer, and the expression in mucinous adenocarcinoma is higher than that in poorly differentiated and moderately and highly differentiated gastric cancer. And the degree of MUC6 loss is closely related to the poor prognosis of gastric cancer.

[0004] In pancreatic cancer cells, upregulating MUC6 expression can inhibit the invasion and migration of tumor cells. In addition, MUC6 can induce the formation of Tn antigens in breast tumor tissues, which can activate Th17 immune cells and promote tumor cell apoptosis to inhibit tumor progression. Therefore, MUC6 plays a very important role in inhibiting the occurrence and development of tumors.

[0005] In the pathological diagnosis of gastrointestinal tumors, MUC6 is often used as an important indicator for immunohistochemistry. By detecting the expression of MUC6 in tumor tissue, pathologists can be assisted in tumor classification, staging and prognosis assessment. For example, in the pathological diagnosis of gastric cancer, the expression of MUC6 can be combined with the expression of other mucins (such as MUC2 and MUC5AC) to jointly determine the pathological type and degree of differentiation of the tumor. Summary of the invention

[0006] The inventors provide an anti-Mucin6 protein monoclonal antibody, wherein the amino acid sequence of the heavy chain variable region of the monoclonal antibody is the amino acid sequence shown in SEQ ID NO.1; the amino acid sequence of the light chain variable region of the monoclonal antibody is the amino acid sequence shown in SEQ ID NO.2.

[0007] Furthermore, the monoclonal antibody is a mouse monoclonal antibody with clone number 37D10.

[0008] The inventors have also provided a method for preparing an anti-Mucin6 protein monoclonal antibody, wherein the antigen used to immunize mice is a recombinant protein, and the recombinant protein is recombinantly expressed by Escherichia coli.

[0009] Furthermore, the recombinant protein comprises a Mucin6 protein fragment and a HIS protein tag.

[0010] Furthermore, the Mucin6 protein fragment is a fragment of positions 1950-2050, which is the amino acid sequence shown in SEQ ID NO.3.

[0011] Furthermore, the plasmid vector used in the recombination process was pET30a.

[0012] The inventors also provide a Mucin6 protein immunoassay reagent, which contains the above-mentioned anti-Mucin6 protein monoclonal antibody as its effective ingredient.

[0013] Furthermore, the immunoassay includes immunohistochemistry, immunoblotting and enzyme-linked immunosorbent assay.

[0014] Different from the prior art, the beneficial technical effects produced by the present invention are as follows: the above technical scheme selects the amino acids at positions 1950-2050 of the Mucin6 protein as antigenic peptides, performs codon optimization, and becomes a gene fragment suitable for expression in Escherichia coli BL21 (DE3), and the recombinant protein finally obtained contains the Mucin6 protein fragment and the histidine protein tag. The recombinant protein is used to immunize mice, and through cell fusion, screening and subcloning, a mouse hybridoma cell line and an anti-Mucin6 protein monoclonal antibody are obtained. The antibodies obtained in this scheme have high specificity and sensitivity, can specifically identify cells expressing the Mucin6 protein, and are suitable for immunological detection, especially immunohistochemical detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 The figure is a comparison of the immunohistochemical staining results of gastric adenocarcinoma; the left one is the antibody prepared by the present invention, and the right one is a commercially available antibody.

[0016] Figure 2 The figure is a comparison of the results of immunohistochemical staining of gastric surface epithelium; the left one is the antibody prepared by the present invention, and the right one is a commercially available antibody. DETAILED DESCRIPTION

[0017] In order to explain in detail the possible application scenarios, technical principles, specific schemes that can be implemented, and the purposes and effects that can be achieved, the following is a detailed description of the specific embodiments listed in conjunction with the accompanying drawings. The embodiments described herein are only used to more clearly illustrate the technical solutions of the present application, and are therefore only used as examples, and cannot be used to limit the scope of protection of the present application.

[0018] Reference to "embodiment" herein means that the specific features, structures or characteristics described in conjunction with the embodiment may be included in at least one embodiment of the present application. The term "embodiment" appearing in various places in the specification does not necessarily refer to the same embodiment, nor does it particularly limit its independence or association with other embodiments. In principle, in the present application, as long as there is no technical contradiction or conflict, the various technical features mentioned in the embodiments can be combined in any way to form a corresponding implementable technical solution.

[0019] Unless otherwise defined, the technical terms used in this document have the same meanings as those generally understood by those skilled in the art to which this application belongs; the use of relevant terms in this document is only for describing specific embodiments and is not intended to limit this application.

[0020] In the description of this application, the term "and / or" is an expression used to describe the logical relationship between objects, indicating that three relationships may exist, for example, A and / or B, which means: A exists, B exists, and A and B exist at the same time. In addition, the character " / " in this article generally indicates that the objects before and after are in an "or" logical relationship.

[0021] In the present application, terms such as “first” and “second” are merely used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual relationship of quantity, priority or sequence between these entities or operations.

[0022] Without further limitations, in this application, the words "include", "comprises", "has" or other similar expressions used in the sentences are intended to cover non-exclusive inclusion. These expressions do not exclude the presence of additional elements in the process, method or product including the elements, so that the process, method or product including a series of elements may include not only those limited elements, but also other elements not explicitly listed, or also include elements inherent to such process, method or product.

[0023] Similar to the understanding in the Examination Guidelines, in this application, expressions such as "greater than", "less than", "exceed" and the like are understood to exclude the number itself; expressions such as "above", "below", "within" and the like are understood to include the number itself. In addition, in the description of the embodiments of this application, "multiple" means more than two (including two), and similar expressions related to "multiple" are also understood in this way, such as "multiple groups", "multiple times", etc., unless otherwise clearly and specifically limited.

[0024] Example 1 Preparation of recombinant Mucin6 protein fragment

[0025] 1. Gene Optimization and Synthesis

[0026] According to the protein sequence of Mucin6 with accession number NP_002470.2 in the NCBI database, the protein fragment of amino acids 1950-2050 was selected and directly optimized into a gene fragment suitable for expression in Escherichia coli BL211 (DE3). During the PCR process, BamH I and XhoI restriction sites were added to the 5' and 3' ends of the gene, respectively.

[0027] The PCR products were separated by agarose gel electrophoresis and recovered. The recovered fusion protein gene and the plasmid vector pET30a used for expression were digested by BamHI and XhoI, respectively, and recovered by electrophoresis again, and connected with T4 DNA ligase. The ligation products were transformed into E. coli competent cells BL211 (DE3), and the clones on the plate were picked and inoculated for bacterial liquid PCR identification. The clones with positive PCR results were selected for sequencing analysis, and the clones with completely correct sequences were used.

[0028] Choosing different antigens for immunization may produce antibodies with different binding properties. The molecule also has multiple variants caused by variable splicing, which ultimately leads to different recognition abilities and patterns of different antibodies for antigen-expressing cells. The Mucin6 molecule was analyzed according to the published sequence. Based on its structure, antigenicity, hydrophilicity and hydrophobicity of the constituent amino acids and secondary structure, a region suitable for soluble expression and good immunogenicity was selected for recombinant expression. The amino acid residues 1950-2050 of Mucin6 were selected for codon optimization, and the molecular weight was about 250kDa. The Mucin6 protein was obtained by sequence optimization design using the prokaryotic expression gene sequence. The recombinant immunogen consists of an antigenic Mucin6 protein fragment and a protein tag for recombinant protein purification, and the protein tag is HIS.

[0029] 2. Protein Expression and Purification

[0030] Transfer the overnight bacteria cultured from a single colony to 100 mL LB medium at a ratio of 1:100, add kanamycin at a final concentration of 10 μg / mL, shake culture at 37°C until OD600 is 0.6-0.8, add 0.5 mmol / L IPTG, shake culture at 16°C overnight, and ultrasonically break the bacteria after harvesting. The recombinant protein has a histidine tag, and a nickel column is used for affinity purification of the protein. Elution is performed with 500 mmol / L imidazole, and SDS PAGE separation and detection are performed. The concentration of the recombinant Mucin6 protein fused with a histidine tag is 0.5 mg / mL, which can be used for animal immunization and antibody screening and identification requirements.

[0031] Example 2 Establishment of hybridoma cell lines

[0032] 1. Immunity

[0033] The recombinant protein in Example 1 was emulsified with Freund's complete adjuvant (Sigma, F5881) and immunized 4-6 week old female ICR mice (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) and injected subcutaneously at 6 points in the abdomen of each mouse at a dose of 20 μg / mouse. The booster immunization was performed once every 14 days, and the antigen was emulsified with Freund's incomplete adjuvant (Sigma, F5506) at a dose of 20 μg / mouse. Seven days after the third booster immunization, the polyantibody titer against the immunogen in the mouse serum was detected by indirect ELISA (wavelength 450nm). The mouse with the highest titer was immunized by tail vein injection, and the antigen was mixed with physiological saline at a dose of 20 μg / mouse.

[0034] 2. Cell Fusion

[0035] Prepare aseptically the spleen cell suspension of immune-qualified mice, mix it with mouse myeloma cells sp2 / 0 (ATCC Number CRL-8287) at a ratio of 5:1, and centrifuge at 1500rpm for 5min. After discarding the supernatant, place the centrifuge tube in a 37℃ water bath, slowly add 1mL of PEG1500 (Roche) within 1 minute, and stir the cells. After standing in warm water for 1min, add 10mL of serum-free IMDM (Sigma), mix well, and centrifuge at 1000rpm for 5min. After discarding the supernatant, add 10mL of serum (PAA) and carefully blow up the cells, and add 5mL of thymocytes mixed with 10×HAT (Sigma) and mix well. Then add 25mL of semi-solid culture medium containing 2.1% nitrocellulose (Sigma) and mix well, and then pour it evenly into 20 cell culture dishes. Place the cell culture dish in a humidified box and culture it in a 37℃ 5% CO2 incubator.

[0036] 3. Cloning and ELISA screening of positive hybridoma cells 37D10

[0037] 7 days after fusion, the size and density of cloned cell clusters are moderate. Under a dissecting microscope, round, solid, and large clone clusters are aspirated and placed in a 96-well culture plate with culture medium prepared in advance, and placed in a 37°C 5% CO2 incubator for culture. After 3 days, the amount of cells accounts for about 2 / 3 of the bottom area. Take 100 μL of supernatant and perform ELISA screening with immunogen and synthetic peptide respectively. The positive clones are completely replaced with 200 μL of complete culture medium containing feeder cells and 1% HT (Sigma). Two days later, a second ELISA screening is performed, and the positive clones are transferred to a 24-well plate with culture medium (containing feeder cells and HT) prepared in advance for culture. Five days later, take 100 μL of supernatant for a third ELISA screening, and the positive clones are successively transferred to 6-well plates and cell culture flasks for expansion and cryopreservation. Example 3 Preparation of monoclonal antibodies by ascites induction method

[0038] 1. Ascites Preparation

[0039] The cells in the logarithmic growth phase were washed with serum-free medium and suspended, and approximately 5 × 10 5 , 1mL. The suspended cells were intraperitoneally injected into mice sensitized with paraffin oil in advance. Ascites was collected 7 days later. The ascites was centrifuged at 4000rpm for 10min at 4℃. The ascites in the middle was carefully aspirated and collected in a centrifuge tube and stored at 4℃ or -20℃.

[0040] 2. Purification of Monoclonal Antibodies

[0041] The antibody was purified from ascites using HiTrap rProtein A FF (GE) affinity chromatography according to the instructions. The purity was determined by SDS-PAGE gel and the concentration was determined by Bradford method. The purified antibody was stored at -20°C.

[0042] Example 4 Monoclonal Antibody Characterization

[0043] 1. Subclass Identification

[0044] Dilute the coated goat anti-mouse IgG (Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.) to 0.5μg / mL with 100mM PBS (pH7.4), add 100μL to each well, and incubate at 4℃ overnight. Pour out the liquid, wash 3 times with PBS containing 0.05% Tween (PBS-T), add 200μL blocking solution (PBS containing 2% BSA and 3% sucrose) to each well, and incubate at 37℃ for 1h. Pour out the liquid, wash 3 times with PBS-T. Add 0.1mL hybridoma supernatant to each well, and incubate at 37℃ for 1h. Pour out the liquid and wash 3 times with PBS-T. 0.1 mL of HRP-labeled goat anti-mouse (κ, λ) antibody diluted 1:1000 or HRP-labeled goat anti-mouse (IgM, IgG1, IgG2a, IgG2b, IgG3, IgA) antibody (Southern Biotech) diluted 1:2000 with blocking solution was added to the appropriate wells and incubated at 37°C for 1 hour. The liquid was emptied and washed 3 times with PBS-T. 50 μL of citric acid buffer (PH4.0) containing 0.15% ABTS (Southern Biotech) and 0.03% H2O2 was added to each well for color development, and the OD value at 405 nm wavelength was measured within 10-20 minutes.

[0045] The results showed that the monoclonal antibody of the present invention is an IgG1 type mouse monoclonal antibody.

[0046] 2. Determination of affinity constant

[0047] The Mucin6 recombinant protein prepared in Example 3 was coated at a coating concentration of 2 μg / mL, 100 μL / well, coated overnight at 4°C, and washed 3 times with PBS-T. 200 μL of blocking solution was added to each well and blocked for 2 hours at 37°C, and washed 3 times with PBS-T. The monoclonal antibody purified in Example 3 was diluted 2 times from 1:200, and a blank control was left in the last well, incubated at 37°C for 1 hour, and washed 3 times with PBS-T. HRP-labeled goat anti-mouse secondary antibody was diluted 1:20000, 100 μL per well, incubated at 37°C for 1 hour, and washed 3 times with PBS-T. 100 μL of citric acid-phosphate buffer containing 0.1% TMB (Sigma) and 0.03% H2O2 was added to each well for color development for 10 minutes, and 50 μL of 0.5M sulfuric acid solution was added to terminate the reaction. The absorbance value at a wavelength of 450 nm was measured with an enzyme reader. Draw a curve of OD value versus antibody dilution multiple, find the dilution multiple A corresponding to half of the maximum binding OD value, and use the following formula to calculate the affinity constant of the antibody to be 1.92×10 9 .

[0048]

[0049] 3. Monoclonal antibody reaction specificity and application effect

[0050] Take the Mucin6 recombinant protein prepared in Example 1, use the immunoblotting method to detect the recognition specificity of the monoclonal antibody of the present invention, and perform 12% polyacrylamide gel electrophoresis. Transfer the gel protein band to a PVDF membrane (Millipore) in a Bio-Rad electrotransfer system according to conventional methods. Place the membrane in a TBS-T blocking solution containing 5% skim milk powder at 4°C overnight. Add the Mucin6 protein monoclonal antibody purified in Example 3 (1:1000 dilution) and incubate at 4°C overnight. After washing the membrane with TBS-T, add a 1:5000 diluted goat anti-mouse secondary antibody (Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.) and incubate at room temperature for 1 hour. Wash the membrane again with TBST, add ECL ultrasensitive colorimetric solution (Beijing Pulilai Gene Technology Co., Ltd.), and use the ChemiDocMP multicolor fluorescence imaging system (Bio-Rad) to collect chemiluminescent image data.

[0051] Example 5 Determination of variable region sequences of antibodies

[0052] Take freshly cultured hybridoma cells and take the supernatant to verify the antigen binding characteristics to confirm that the cell line used for cloning can indeed secrete the required antibodies. After the results are confirmed, centrifuge and collect for 10 6The above hybridoma cells. Trizol method was used to extract total RNA of hybridoma cells. 9 μL of total RNA was taken, 2.5 μL of oligo(dT)12–18primer (10 mM) and 5 μL of dNTPs were added, mixed evenly, kept at 70°C for 5 minutes and then placed on ice for 5 minutes, or denatured according to the reverse transcriptase used. Subsequently, 5 μL of RTbuffer (5×), 2.5 μL of DTT (0.1 M) and 1 μL of reverse transcriptase were added, and the reaction was carried out at 42°C for 1 hour. The reaction was terminated by incubation at 70°C for 15 minutes, and the obtained cDNA was stored at -20°C. The first-strand cDNA obtained was subjected to PCR amplification, and 25 pmol of each primer was added to the 50 μL reaction system. The sequences of the primers for amplification of the heavy chain variable region and the light chain variable region were designed and synthesized according to the mouse monoclonal antibody primer sequences in the book "Recombinant Antibodies" edited by Shen Beifen (Science Press, published in 2005).

[0053] The remaining dNTPs and buffer were added as usual, and finally 1 μL of cDNA template and 1U hot start Taq DNA polymerase were added. The PCR amplification program was set to 94°C for 40 seconds, 52°C for 40 seconds, and 72°C for 40 seconds for 20 to 25 cycles, and finally extended at 72°C for 3 minutes. The product can be placed at 4°C for standby or directly electrophoresed. Take 20 μL of PCR product for electrophoresis analysis and separate on 1.5% agarose gel. The length of the light chain (κ light chain) is between 320-340 bp, and the length of the heavy chain is between 340-370 bp. When there is a specific product in this region, the gel is cut and recovered, cloned into a T vector or expression vector for sequencing.

[0054] Example 6. Immunohistochemical tissue chip staining and identification

[0055] 1. Chip preparation process

[0056] Each sample was first stained with HE slices to determine the tumor site. The tissue chip was made using the fully automatic tissue chip instrument of 3DHISTECH. The prepared tissue chip wax block was placed in the wax block mold, placed in a 68°C oven for 10 minutes, so that the tissue core and the wax of the receptor wax block were integrated, and then the mold was gently removed from the oven, and the semi-melted paraffin was allowed to cool at room temperature for about 30 minutes, and then placed in a -20°C refrigerator for 6 minutes. After the tissue chip wax block was removed from the mold, sliced ​​or placed in a 4°C refrigerator for later use. After trimming, continuous sections were made with a thickness of 3μm. The continuous sections were floated in 40% alcohol and allowed to unfold naturally. The separated sections were then transferred to 50°C warm water for 30 seconds, and the sections were mounted on slides treated with polylysine. The prepared tissue chip was placed in a 68°C oven for 2 hours, taken out, cooled at room temperature, and stored in a -4°C refrigerator.

[0057] II. IHC staining and analysis

[0058] Dewax in conventional xylene for 3 times, 6 minutes each time, hydrate in 100%, 100%, 95%, 85% gradient ethanol, 3 minutes each time, and finally rinse with tap water. Perform antigen retrieval, then place the slices in a wet box and rinse with PBS for 3×3 minutes. Add 3% H2O2 for 10 minutes, and rinse with PBS for 3×3 minutes. Shake dry the slices, add the primary antibody diluted in an appropriate proportion (the first dilution is designed according to the antibody concentration) and incubate at room temperature (25°C) for 1 hour, rinse with PBS for 3×3 minutes, add the secondary antibody and incubate at room temperature for 15-30 minutes, rinse with PBS for 3×3 minutes, shake off PBS, and use freshly prepared DAB color development solution for 3-10 minutes. Counterstain with hematoxylin for 25 seconds, and return to blue with PBS for 30 seconds. Dehydrate in a gradient of 85% (3 minutes)-95% (3 minutes)-100% (3 minutes)-100% (3 minutes) alcohol, and finally transparentize with xylene for 3 minutes and seal with neutral gum.

[0059] Immunohistochemical staining results are divided into: positive and negative. Positive expression must be in specific antigenic sites of cells and tissues to be considered positive. In the case of clear tissue staining distribution and accurate cell localization, the staining results are further divided according to the difference in staining intensity, as follows:

[0060] 1. The sample is weakly positive; marked as "+";

[0061] 2. The sample is moderately positive; marked as "++";

[0062] 3. The sample is highly positive; marked as "+++".

[0063] 4. The sample is negative and marked as “-”.

[0064] 3. Data Statistics

[0065] 1. Tumor tissue chip test results:

[0066] The antibody Mucin6 (37D10) and the commercially available antibody Mucin6 (MRQ-20) were simultaneously tested on 55 cases of gastric adenocarcinoma and the test results were compared.

[0067] The immunohistochemical results of Mucin6 were statistically analyzed. The whole experiment process adopted a double-blind design, and the statistical results are as follows:

[0068]

[0069] The results showed that the anti-Mucin6 protein monoclonal antibody prepared by the present invention had accurate staining positioning, clear staining without nonspecific staining, and a clean background. In immunohistochemical detection, the positive rate and positive intensity were higher than those of commercially available antibodies. This shows that the Mucin6 of the present invention has higher sensitivity and effectively avoids false negative results.

[0070] Figure 1 The figure is a comparison of the immunohistochemical staining results of gastric adenocarcinoma (the left one is the antibody prepared by the present invention, and the right one is a commercially available antibody).

[0071] 2. Normal tissue chip test results:

[0072] The normal tissue array includes 30 normal tissue samples, which are mainly selected from fresh and timely fixed surgical specimens; each tissue includes 3 different case samples. The 30 normal tissues include: brain, heart, cerebellum, esophagus, adrenal gland, stomach, ovary, small intestine, pancreas, colorectum, parathyroid gland, liver, pituitary gland, salivary gland, testis, kidney, thyroid gland, prostate gland, breast, uterus, spleen, bladder, tonsil, skeletal muscle, thymus (infants), skin, bone marrow, peripheral nerve, lung, and mesothelial cells.

[0073] The present antibody (37D10) and commercially available antibodies were simultaneously tested on normal tissue chips, and the positive and negative test results were consistent, indicating that the specificity of the present antibody in normal tissues is equivalent to that of the commercially available antibodies.

[0074] Figure 2 The figure is the result of immunohistochemical staining of gastric surface epithelium (the left one is the antibody prepared by the present invention, and the right one is a commercially available antibody).

[0075] Finally, it should be noted that although the above embodiments have been described in the specification and drawings of this application, this does not limit the scope of patent protection of this application. All technical solutions generated by replacing or modifying equivalent structures or equivalent processes based on the essential concept of this application using the contents recorded in the specification and drawings of this application, as well as directly or indirectly implementing the technical solutions of the above embodiments in other related technical fields, are included in the scope of patent protection of this application.

Claims

1. An anti-Mucin6 protein monoclonal antibody, characterized in that: The amino acid sequence of the heavy chain variable region of the monoclonal antibody is the amino acid sequence shown in SEQ ID NO.1; the amino acid sequence of the light chain variable region of the monoclonal antibody is the amino acid sequence shown in SEQ ID NO.

2.

2. The monoclonal antibody according to claim 1, characterized in that The monoclonal antibody is a mouse monoclonal antibody with a clone number of 37D10.

3. A method for preparing an anti-Mucin6 protein monoclonal antibody, characterized in that: The antigen used for immunizing mice is a recombinant protein, which is recombinantly expressed by Escherichia coli.

4. The preparation method according to claim 3, characterized in that: The recombinant protein comprises a Mucin6 protein fragment and a HIS protein tag.

5. The preparation method according to claim 4, characterized in that: The Mucin6 protein fragment is a fragment of sites 1950-2050, which is the amino acid sequence shown in SEQ ID NO.

3.

6. The preparation method according to claim 3, characterized in that: The plasmid vector used in the recombination process was pET30a.

7. A Mucin6 protein immunoassay reagent, characterized in that: The immunoassay reagent contains the anti-Mucin6 protein monoclonal antibody according to claim 1 as its effective ingredient.

8. The immunoassay reagent according to claim 7, characterized in that: The immunoassay includes immunohistochemistry, immunoblotting and enzyme-linked immunosorbent assay.

Citation Information

Patent Citations

  • Anti-human mucoglycoprotein 6 (MUC6) rabbit monoclonal antibody and application thereof

    CN116554333A

  • Enzymatic large-scale synthesis of mucin glyconjugates, and immunogenic applications thereof

    EP1808442A1